Dasatinib

What is Dasatinib?

Dasatinib is an oral medication classified as a tyrosine kinase inhibitor (TKI), primarily used in the treatment of certain types of leukemia. It works by blocking the activity of several oncogenic tyrosine kinases, which are enzymes that play a crucial role in the growth and proliferation of cancer cells. Specifically, Dasatinib targets the BCR-ABL fusion protein, a hallmark of chronic myeloid leukemia (CML), as well as other kinases like SRC family kinases, c-KIT, and PDGFR. This multi-targeted approach makes Dasatinib a potent agent against resistant forms of these cancers.

The development of Dasatinib marked a significant advancement in cancer therapy, particularly for patients who had developed resistance or intolerance to imatinib, another first-generation TKI. Approved by the U.S. Food and Drug Administration (FDA) in 2006, Dasatinib quickly became a cornerstone in the management of CML and acute lymphoblastic leukemia (ALL). Its introduction provided a vital alternative, improving remission rates and overall survival for patients facing limited treatment options. The drug's ability to bind to both active and inactive conformations of the BCR-ABL kinase contributes to its effectiveness against mutations that confer resistance to other TKIs.

As a second-generation TKI, Dasatinib (ATC code: L01EA02, within the broader L05 category for antineoplastic agents) represents a targeted therapy that offers a more refined approach to cancer treatment compared to traditional chemotherapy. It is designed to specifically interfere with molecular pathways involved in cancer development, thereby minimizing damage to healthy cells and reducing the severity of side effects typically associated with less targeted treatments. This precision medicine approach has revolutionized the prognosis for patients with specific forms of leukemia, turning what was once a rapidly fatal disease into a manageable chronic condition for many.

⚙️ Mechanism of Action

The primary mechanism of action for Dasatinib involves its potent inhibition of multiple tyrosine kinases, most notably the BCR-ABL fusion protein. The BCR-ABL kinase is an abnormal protein found in chronic myeloid leukemia (CML) and some cases of acute lymphoblastic leukemia (ALL), resulting from a chromosomal translocation known as the Philadelphia chromosome. This constitutively active kinase drives uncontrolled cell proliferation, inhibits apoptosis (programmed cell death), and promotes cell survival, leading to the malignant transformation of hematopoietic stem cells. Dasatinib binds to the ATP-binding site of the BCR-ABL kinase, preventing it from phosphorylating its substrates and thus shutting down the downstream signaling pathways that fuel leukemia cell growth.

What distinguishes Dasatinib from some other TKIs is its ability to bind to both the active and inactive conformations of the ABL kinase domain. This dual binding capability is crucial for overcoming resistance mutations that affect the ATP-binding pocket, which can render other TKIs ineffective. Beyond BCR-ABL, Dasatinib also potently inhibits SRC family kinases (e.g., SRC, LCK, YES, FYN), c-KIT, PDGFRβ, and ephrin receptor kinases. The inhibition of SRC family kinases, in particular, contributes to its antileukemic activity and may play a role in its efficacy against certain resistant CML clones. This broad-spectrum tyrosine kinase inhibition profile contributes to its robust clinical efficacy in patients with Philadelphia chromosome-positive (Ph+) CML and ALL.

• Potent inhibitor of BCR-ABL tyrosine kinase, vital for CML and Ph+ ALL.
• Binds to both active and inactive conformations of the ABL kinase, overcoming resistance.
• Inhibits SRC family kinases (SRC, LCK, YES, FYN), contributing to its antileukemic effect.
• Targets other kinases including c-KIT and PDGFRβ, broadening its therapeutic scope.
• Disrupts downstream signaling pathways crucial for cancer cell proliferation and survival.

🏥️ Medical Uses & Indications

Dasatinib is a highly effective targeted therapy with specific indications in hematologic malignancies. Its potent inhibitory action against key oncogenic kinases makes it a valuable treatment option for patients who have specific genetic markers associated with their disease. The primary goal of Dasatinib therapy is to achieve deep and durable remissions, improve patient survival, and enhance the quality of life for individuals battling these challenging cancers. It is often used after initial therapies have failed or for patients who cannot tolerate other treatments.

Primary Indications

• Newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.
• Adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy, including imatinib.
• Adults with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) with resistance or intolerance to prior therapy.
• Pediatric patients with newly diagnosed Ph+ CML in chronic phase.
• Pediatric patients with Ph+ ALL that is resistant or intolerant to prior therapy or who have relapsed after stem cell transplant.
• Treatment of Ph+ ALL in combination with chemotherapy for adults.

Secondary / Off-label Uses

• Studies are exploring Dasatinib in other solid tumors or hematologic malignancies that exhibit specific kinase mutations sensitive to Dasatinib's inhibitory profile.
• Investigation into its potential role in certain myelodysplastic syndromes (MDS) or myeloproliferative neoplasms (MPN) with specific genetic alterations.
• Research on its anti-fibrotic properties in conditions like pulmonary fibrosis, although this remains highly experimental and off-label.

💊 Dosage & Administration

The dosage of Dasatinib is carefully determined by the treating physician based on the specific indication, patient's response to therapy, and tolerability. It is available in tablet form and is taken orally, typically once daily. It can be taken with or without food, but consistency in timing is often recommended. Adherence to the prescribed regimen is crucial for treatment success, and patients should never adjust their dose or discontinue the medication without consulting their healthcare provider.

Important: Always follow your prescriber instructions. Dosages vary by weight, age, and condition, and may be adjusted based on efficacy and side effect management. Do not crush, cut, or chew Dasatinib tablets.

⚠️ Side Effects

Like all medications, Dasatinib can cause side effects, ranging from mild to severe. Patients should be aware of potential adverse reactions and report any concerning symptoms to their healthcare provider promptly. The incidence and severity of side effects can vary greatly among individuals.

Common Side Effects (>10%)

• Myelosuppression (low blood cell counts, e.g., neutropenia, thrombocytopenia, anemia)
• Fluid retention (e.g., pleural effusion, peripheral edema)
• Diarrhea
• Headache
• Nausea
• Rash

Less Common (1-10%)

• Fatigue
• Abdominal pain
• Musculoskeletal pain
• Dyspnea (shortness of breath)
• Cough
• Vomiting
• Infections (e.g., upper respiratory tract infection)

Rare but Serious

• Pulmonary Arterial Hypertension (PAH): A serious condition characterized by high blood pressure in the arteries of the lungs, potentially leading to heart failure. Patients should be monitored for new or worsening shortness of breath, fatigue, or swelling.
• Cardiac Dysfunction: Can include heart failure, left ventricular dysfunction, and arrhythmias. Regular cardiac monitoring is recommended, especially for patients with pre-existing heart conditions.
• Hemorrhage: Serious bleeding events, including gastrointestinal or intracranial hemorrhage, can occur. This risk is increased in patients with low platelet counts or those on anticoagulant therapy.

🔄 Drug Interactions

Dasatinib is metabolized primarily by the cytochrome P450 3A4 (CYP3A4) enzyme system. Therefore, co-administration with drugs that either inhibit or induce CYP3A4 can significantly alter Dasatinib concentrations in the body, potentially leading to increased toxicity or reduced efficacy. It is crucial for patients to inform their doctor and pharmacist about all medications, supplements, and herbal products they are taking to avoid harmful interactions.

• Strong CYP3A4 Inhibitors: Drugs like ketoconazole, itraconazole, clarithromycin, and ritonavir can increase Dasatinib levels, leading to increased side effects. Co-administration should be avoided or managed with dose adjustments.
• Strong CYP3A4 Inducers: Medications such as rifampin, phenytoin, carbamazepine, and St. John's Wort can decrease Dasatinib levels, potentially reducing its effectiveness. These combinations should be avoided.
• Proton Pump Inhibitors (PPIs) and H2 Blockers: Drugs like omeprazole, pantoprazole, famotidine, and ranitidine reduce gastric acid secretion, which can decrease the solubility and absorption of Dasatinib. Antacids are generally preferred for managing stomach acid, but should be taken at least 2 hours before or after Dasatinib.
• Anticoagulants and Antiplatelet Agents: Co-administration with warfarin, heparin, aspirin, or clopidogrel may increase the risk of bleeding, especially given Dasatinib's potential to cause thrombocytopenia.
• QTc-Prolonging Drugs: Dasatinib can prolong the QTc interval, and co-administration with other drugs known to prolong QTc (e.g., certain antiarrhythmics, antipsychotics) may increase the risk of cardiac arrhythmias.
• Grapefruit Juice: Grapefruit and grapefruit juice can inhibit CYP3A4 and increase Dasatinib concentrations. Patients should avoid consuming grapefruit products during treatment.

🚫 Contraindications & Warnings

While Dasatinib is a life-saving medication for many, certain conditions and patient characteristics necessitate caution or outright contraindicate its use. A thorough medical history and ongoing monitoring are essential to ensure patient safety and optimize treatment outcomes.

• Hypersensitivity: Patients with a known severe hypersensitivity to Dasatinib or any of its excipients should not use this medication.
• Pregnancy and Breastfeeding: Dasatinib can cause fetal harm when administered to a pregnant woman and is excreted in human milk. It is contraindicated during pregnancy and breastfeeding. Women of childbearing potential should use effective contraception during treatment and for a period after.
• Severe Hepatic Impairment: Patients with severe liver dysfunction may have altered metabolism of Dasatinib, leading to increased drug exposure and potential toxicity. Dose adjustments or avoidance may be necessary.
• Pre-existing Cardiac Conditions: Caution is advised in patients with a history of cardiac disease, including prolonged QTc interval, uncontrolled hypertension, or significant cardiac events, due to the risk of cardiac dysfunction and QTc prolongation.
• Pulmonary Hypertension: Patients should be carefully monitored for signs and symptoms of pulmonary hypertension, and Dasatinib should be discontinued if PAH is confirmed.
• Lactose Intolerance: Dasatinib tablets contain lactose, which may be relevant for patients with severe lactose intolerance.

Medical Disclaimer: This information is for educational purposes only. Always consult a qualified healthcare professional before starting, stopping, or changing any medication.

❓ Frequently Asked Questions

Is Dasatinib safe for long-term use?

Dasatinib is often prescribed for long-term use, especially in chronic myeloid leukemia (CML), where treatment may continue indefinitely to maintain remission and prevent disease progression. Clinical studies have demonstrated its long-term efficacy and an acceptable safety profile, with many patients tolerating the medication for years. However, long-term use requires continuous monitoring for potential side effects, including fluid retention, cardiovascular issues, and pulmonary complications. Regular check-ups, blood tests, and adherence to medical advice are crucial to manage any emerging adverse events and ensure the ongoing safety and effectiveness of Dasatinib therapy.

Can Dasatinib be taken with food?

Yes, Dasatinib can be taken with or without food. Unlike some other medications where food intake significantly impacts absorption, studies have shown that the bioavailability of Dasatinib is not substantially altered by food. However, it is generally recommended to take Dasatinib at approximately the same time each day to maintain consistent drug levels in the body and maximize its therapeutic effect. It is important to avoid grapefruit juice while on Dasatinib, as it can interfere with the drug's metabolism and increase its concentration.

What should I do if I miss a dose of Dasatinib?

If you miss a dose of Dasatinib, you should not take an extra dose to make up for the missed one. Instead, simply take your next scheduled dose at its regular time. Do not double the dose to compensate for the missed one, as this can increase the risk of side effects. If you frequently miss doses or are unsure about what to do, it is essential to contact your doctor or pharmacist for guidance. Consistent adherence to the prescribed dosing schedule is vital for the optimal effectiveness of Dasatinib in treating your condition.

Where can I buy Dasatinib?

Dasatinib is a prescription-only medication, meaning it cannot be purchased over-the-counter. It must be prescribed by a licensed healthcare professional, typically an oncologist or hematologist, who can assess your medical condition and determine if Dasatinib is the appropriate treatment for you. You can obtain Dasatinib from licensed pharmacies upon presenting a valid prescription. It is crucial to purchase Dasatinib only through legitimate and regulated medical channels to ensure you receive a genuine, safe, and effective product. Avoid purchasing medications from unverified online sources or without a prescription, as this can pose significant health risks.